unrecectable or recurrent advanced gastric cancer
Conditions
Interventions
Patients receive 180mg of nab-paclitaxel per square meter of body-surface area on day 1 of every 21-day cycle. The patients continue therapy until disease progression or prohibitive toxic effects occu
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Unresectable or recurrent advanced gastric cancer 2.Histologically confirmed adenocarcinoma, signet ring cell caricinoma and mucinous adenocarinoma. 3.Prior treatment by chemothrapy including 5-FU regimen 4.No central nurve metastasis 5.Age from 20 to 65 years old 6.Performance status is 0,1,2. 7.Required baseline laboratory data.(within 14 days of registration) Neu 1,500mm3 PLT 100,000mm3 T-Bil 1.5mgdL AST 100IU/L ALT 100IU/L serum creatine 1.5mg/dL 8.Expected survival time more than 90 days 9.The patient has previously given written, informed consent to participate in this study
Exclusion criteria
Exclusion criteria: 1.With history of receiving paclitaxel treatment 2.With serious drug allergy 3.With servaral comorbid disease poorly controlled diabetes poorly controlled hypertension liver cirrhosis, liver failure renal failure intestitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema active infectious disease heart failure, myocardial infarction, angina pectoris or ECG abnormalities within 6 months 4.With active anothor cancer 5.With peripheral neuropathy greater than grade2 6.With HBs antigen positive 7.With pregnant or nursing women 8.Cases who physician judged improper to entry this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival(OS),Progression free survival(PFS),Safty, Time to progression(TTP) | — |
Countries
Japan
Contacts
Public ContactRyo Takagawa
Yokohama City University Medical Center Gastroenerological Center
Outcome results
None listed